Eltacin
Pharmacotherapeutic group: Antioxidant drug
ATC code: C01EX
Pharmacological properties:
Eltacin® contains the mix of nonessential amino acids: Glycine, L-glutamic acid and L-cystine, which are act as a metabolic regulator: increase the intracellular level of glutathione and activity of glutathione-dependent enzymes, normalize oxidation-reduction processes and oxygen utilization in tissues; as a result, the drug is able to:
- have an antioxidant (decreasing level of free radicals, peroxide compounds and malondialdehyde) and anti-hypoxic (increasing organism resistance to hypoxia, intensifying the ATP synthesis) effect;
- enhance the myocardial contractility;
- enhance physical tolerance;
- enhance life quality of patients with heart failure (increasing the social integration, improving psycho-emotional state);
- speed up recovery of working efficiency after strenuous exercise in children.
Indications
- Chronic heart failure (I-III NYHA functional classes, on background of basic therapy) in adults;
- chronic heart failure (I-II NYHA functional classes, on background of basic therapy) in children of 12-18 years;
- vegetative dysfunction syndrome in children of 12-18 years;
- prevention of chronic overexertion and recovery after strenuous exercise whilst sports activities in children of 11-15 years.
Contraindications
Individual hypersensitivity to the drug, age under 11 (efficiency and safety are not determined).
Pregnancyandlactation.
Clinical trials of Eltacin® during pregnancy and lactation were not conducted. Not recommended to use during pregnancy and lactation.
Dosageandadministration:
Sublingually. It also possible to chew the tablet and place it under the tongue till it completely dissolve.
Chronic heart failure (I-III NYHA functional classes) in adults: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.
Chronic heart failure (I-II NYHA functional classes) in children of 12-18 years: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.
Vegetative dysfunction syndrome in children of 12-18 years: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.
Prevention of chronic overexertion in children of 11-15 years: 1 tablet 2 times a day for 2-3 weeks.
Recovery after strenuous exercise whilst sports activities in children of 11-15 years: 1 tablet 3 times a day for 2 weeks.
Adverse reactions
Allergic reactions are possible.
Overdosage
No cases of overdose occured.
Drug interactions
There is no information about drug interactions.
Precautions
It is possible to take Eltacin® together with angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, aldosterone antagonists, organic nitrates, and calcium channel-blocking agents.
Dosage form
70 mg + 70 mg + 70 mg sublingual tablets.
Blister with 30 tablets in cardboard pack together with the patient information leaflet.
Storage conditions
Store in a dry place at a temperature under 25 °C, protect from light.
Keep out of the reach of children.
Shelf life
3 years. Do not use after labeled expiration date.
Prescription status
No prescription required.
Manufacturer / For reclamations:
Ltd. “Medical Research and Production Complex “BIOTIKI”
Address: 6-th Radial’naya Street. 24-14, 115404 Moscow, Russian Federation,
phone: +7 (495) 327-53-53.